Explore
Validate
Learn12-1839-42
antibody from Invitrogen Antibodies
Targeting: CXCR3
CD183, CKR-L2, CMKAR3, GPR9, IP10-R, MigR
Flow cytometryAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Flow cytometry [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 12-1839-42 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CD183 (CXCR3) Monoclonal Antibody (CEW33D), PE, eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Yellow dye
- Isotype
- IgG
- Antibody clone number
- CEW33D
- Vial size
- 100 Tests
- Concentration
- 5 µL/Test
- Storage
- 4° C, store in dark, DO NOT FREEZE!
Submitted references Application of the chemokine-chemokine receptor axis increases the tumor-targeted migration ability of cytokine-induced killer cells in patients with colorectal cancer.
Chloroquine inhibits human CD4(+) T-cell activation by AP-1 signaling modulation.
Subsets of human CD4(+) regulatory T cells express the peripheral homing receptor CXCR3.
Zou Y, Liang J, Li D, Fang J, Wang L, Wang J, Zhang J, Guo Q, Yan X, Tang H
Oncology letters 2020 Jul;20(1):123-134
Oncology letters 2020 Jul;20(1):123-134
Chloroquine inhibits human CD4(+) T-cell activation by AP-1 signaling modulation.
Schmidt RL, Jutz S, Goldhahn K, Witzeneder N, Gerner MC, Trapin D, Greiner G, Hoermann G, Steiner G, Pickl WF, Burgmann H, Steinberger P, Ratzinger F, Schmetterer KG
Scientific reports 2017 Feb 7;7:42191
Scientific reports 2017 Feb 7;7:42191
Subsets of human CD4(+) regulatory T cells express the peripheral homing receptor CXCR3.
Hoerning A, Koss K, Datta D, Boneschansker L, Jones CN, Wong IY, Irimia D, Calzadilla K, Benitez F, Hoyer PF, Harmon WE, Briscoe DM
European journal of immunology 2011 Aug;41(8):2291-302
European journal of immunology 2011 Aug;41(8):2291-302
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Staining of normal human peripheral blood cells with Anti-Human CD3 FITC (Product # 11-0038-42) and Mouse IgG1 K Isotype Control PE (Product # 12-4714-81) (left) or Anti-Human CD183 (CXCR3) PE (right). Cells in the lymphocyte gate were used for analysis.
- Conjugate
- Yellow dye
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- 3 Co-expression of CXCR3 with FOXP3, CTLA-4 and CD39 on CD4 + T cells. (A and B) Representative flow cytometry plots illustrating co-expression of CXCR3 and CD25 on (A) the CD4 + FOXP3 + T-cell subset and (B) the CD4 + CTLA-4 + subset. Staining with isotype control antibodies is shown on the right of each dot plot. (C) Median, 25th and 75th percentile and range of CXCR3 expression on CD4 + FOXP3 + or CD4 + CTLA-4 + subsets. (D and E) Representative flow cytometry plots of CXCR3 expression on (D) double positive FOXP3 + CTLA-4 + cells and (E) FOXP3 + CD39 + cells after gating on CD4 + cells. The box plot on the right of each panel illustrates median, 25th and 75th percentile and range of expression in multiple experiments. (F) Fold difference (mean+SEM) in mRNA expression for Tbet in sorted populations of CD4 + CD25 hi CXCR3 pos cells (white bars) or CD4 + CD25 hi CXCR3 neg Tregs (black bars). Expression was evaluated in unactivated Tregs (left panel) or in Tregs following 6 h activation with anti-CD3/anti-CD28 (right panel). Representative of n =3 experiments with similar results.
- Conjugate
- Yellow dye
